D
DOD Biotech PCL
SET:DOD
DOD Biotech PCL
SET:DOD
Price:
1.67
THB
-3.47%
Market Cap:
฿752.2m
Balance Sheet
Balance Sheet Decomposition
DOD Biotech PCL
DOD Biotech PCL
Balance Sheet Decomposition is not available for
DOD Biotech PCL
DOD Biotech PCL
Balance Sheet
DOD Biotech PCL
DOD Biotech PCL
Currency: THB
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
22
|
78
|
47
|
112
|
137
|
82
|
143
|
162
|
30
|
|
| Cash |
22
|
78
|
47
|
112
|
137
|
82
|
143
|
162
|
30
|
|
| Short-Term Investments |
0
|
0
|
0
|
5
|
300
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
7
|
40
|
40
|
51
|
64
|
216
|
271
|
337
|
57
|
|
| Accounts Receivables |
7
|
40
|
40
|
51
|
63
|
216
|
263
|
315
|
39
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
8
|
22
|
18
|
|
| Inventory |
85
|
49
|
21
|
23
|
25
|
115
|
246
|
113
|
98
|
|
| Other Current Assets |
59
|
18
|
15
|
7
|
9
|
27
|
13
|
13
|
12
|
|
| Total Current Assets |
173
|
185
|
123
|
198
|
534
|
440
|
673
|
626
|
197
|
|
| PP&E Net |
14
|
100
|
233
|
250
|
302
|
861
|
922
|
967
|
976
|
|
| PP&E Gross |
14
|
100
|
233
|
250
|
302
|
861
|
922
|
967
|
976
|
|
| Accumulated Depreciation |
3
|
7
|
15
|
33
|
53
|
96
|
159
|
253
|
301
|
|
| Intangible Assets |
0
|
0
|
1
|
1
|
1
|
28
|
11
|
6
|
6
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
108
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
401
|
120
|
106
|
3
|
3
|
|
| Other Long-Term Assets |
0
|
0
|
12
|
5
|
169
|
17
|
45
|
25
|
110
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
108
|
0
|
0
|
0
|
|
| Total Assets |
187
N/A
|
285
+52%
|
370
+30%
|
454
+23%
|
1 407
+210%
|
1 575
+12%
|
1 758
+12%
|
1 627
-7%
|
1 291
-21%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
52
|
13
|
10
|
20
|
7
|
83
|
181
|
93
|
80
|
|
| Accrued Liabilities |
4
|
8
|
8
|
17
|
6
|
23
|
32
|
14
|
17
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
10
|
93
|
130
|
77
|
149
|
|
| Current Portion of Long-Term Debt |
0
|
3
|
10
|
10
|
1
|
50
|
48
|
34
|
22
|
|
| Other Current Liabilities |
17
|
19
|
35
|
70
|
192
|
38
|
77
|
42
|
35
|
|
| Total Current Liabilities |
72
|
43
|
63
|
117
|
216
|
289
|
468
|
259
|
304
|
|
| Long-Term Debt |
20
|
16
|
41
|
43
|
1
|
33
|
27
|
73
|
58
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
5
|
24
|
12
|
11
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
19
|
11
|
18
|
6
|
|
| Other Liabilities |
0
|
2
|
4
|
5
|
5
|
10
|
13
|
21
|
25
|
|
| Total Liabilities |
92
N/A
|
61
-34%
|
108
+77%
|
165
+53%
|
222
+35%
|
355
+60%
|
544
+53%
|
346
-36%
|
404
+17%
|
|
| Equity | ||||||||||
| Common Stock |
50
|
90
|
150
|
150
|
205
|
205
|
205
|
205
|
205
|
|
| Retained Earnings |
45
|
134
|
112
|
140
|
38
|
143
|
69
|
185
|
209
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
940
|
940
|
940
|
891
|
891
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
1
|
69
|
0
|
0
|
0
|
|
| Total Equity |
95
N/A
|
224
+136%
|
262
+17%
|
290
+10%
|
1 184
+309%
|
1 219
+3%
|
1 214
0%
|
1 281
+5%
|
887
-31%
|
|
| Total Liabilities & Equity |
187
N/A
|
285
+52%
|
370
+30%
|
454
+23%
|
1 407
+210%
|
1 575
+12%
|
1 758
+12%
|
1 627
-7%
|
1 291
-21%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
100
|
180
|
300
|
300
|
410
|
410
|
411
|
411
|
411
|
|
Switch to:
Switch to:
See Also
Discover More
